Dr. Bryan Ardis explains how hospital protocols are killing people

  • Post category:COVID-19

In this 30 min presentation Doctor Bryan Ardis takes us through the reason why death rate from Covid-19 is higher in the US than any other country. He attributes it to the one and only treatment protocols mandated by the NIH that hospitals should use, and that is: Remdesivir – a medication that is currently under evaluation. 


Remdesivir was used in a “Randomized Controlled Trial of Ebola Virus Disease Therapeutics where it killed 53.1% of patients and had to be pulled out of the study before it ended.  

Faustian Fauci mandates Remdesivir despite overwhelming evidence it may leads to organ failure

Dr Ardis rightly asks why did Antony Fauci which was overseeing this study for over a year selected the one drug that killed more people than any of the other 3 which were used in the ebola trial?
One could argue this was Ebola and here we have Covid-19. True but… Lets look at other trials where Remdesivir was used as treatment for Covid-19:
Another study mentioned was done by Gilead’s Compassionate Use Program where  53 Patients Treated With Investigational Antiviral Remdesivir in the United States, Europe, Canada and Japan for 10 days. According to Gilead press releaseRemdesivir treatment resulted in clinical improvement in 68 percent of patients” this fact was highlighted in the subtitle, however tucked away in the text we find the overall mortality rate in this cohort was 13 percent (n=7/53).”and “The mortality rate was higher in the subgroup of patients on invasive ventilation (18 percent, n=6/34), compared with patients on noninvasive oxygen support (5 percent, n=1/19).
Later on we find out that only 75% received the full 10-day course of Remdesivir so what happened to the other 25% ?  

“The planned treatment was a 10-day course of Remdesivir, consisting of a 200 mg loading dose administered intravenously on day 1, followed by 100 mg daily for the remaining nine treatment days. Of the 53 patients included in the analysis, 75 percent received the full 10-day course of Remdesivir, 19 percent received 5-9 days of treatment, and 6 percent received fewer than 5 days of treatment. Follow-up continued through 28 days after initiation of Remdesivir treatment. Four patients discontinued Remdesivir prematurely, one due to worsening of pre-existing renal failure, one due to multiple organ failure and two due to elevated liver enzymes, including one patient with a maculopapular rash.”

Remedesivir patent is owned by Gilead who also manufactures it.

Another study using Remdesivir for covid 19 was conducted in France Sept 2020: Case report study of the first five COVID-19 patients treated with Remdesivir in France” where “The treatment had to be interrupted in four of the five patients, because of ALT elevation and/or renal failure.”

In May 2021  another study was conducted titled “Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database”. Searching the databases (VigiBase) of the World Health Organization (WHO) for internationally reported combination of the terms “acute renal failure” and “Remdesivir”. It also compared it with reported cases with other drugs prescribed in comparable situations of COVID-19: hydroxychloroquine, tocilizumab, and lopinavir/ritonavir. The study found that Acute renal failure associated with the use of Remdesivir could be over 20 times more than in the use of the other drugs.

Table 2. ROR for the SMQ ARF (broad) associated with Remdesivir
Exposure Cases of ARF Non-cases ROR [95% confidence interval]
Comparator drugsa 138 7,385 /
Remdesivir 138 363 20.3 [15.7–26.3] (P < 0.0001)
  • ARF, acute renal failure; ROR, reporting odds ratio; SMQ, Standardized MedDRA version 23.0 Query.
  • a Hydroxychloroquine, tocilizumab, and lopinavir/ritonavir.

In Nov 2020 an article published by CNBC reports on 

“A World Health Organization panel advised doctors against using Gilead Sciences’ antiviral drug remdesivir as a treatment for patients hospitalized with Covid-19, saying there is currently “no evidence” that it improves survival or shortens recovery time — standing in stark contrast to U.S. regulatory guidance on the drug.

The WHO Guideline Development Group, a panel of international experts who provide advice to the agency, said its recommendation is based on new data comparing the effects of several drug treatments, including data from four international randomized trials involving more than 7,000 patients hospitalized with the disease. 

The WHO panel acknowledged that evidence so far does not prove that remdesivir “has no benefit.” But it added given the possibility of harm as well as the high cost and resources need to administer the drug, it is an “appropriate recommendation.” The group said it supports continued enrollment in trials evaluating the drug.” 

The recommendation was published in the British medical trade journal The BMJ on Friday in the U.K.

Despite the clear signals of multiple organ failure, Remdesivir remains the poison of choice to this day when it comes to hospital treatment for Covid 19. And not just in the USA.

Where else in the world Remedesivir has been used?

According to Reuters article from Oct 22, 2020 Gilead’s Remdesivir is “at the forefront in the fight against the novel coronavirus as one of the first drugs to have shown to be effective in countering COVID-19 in human trials…. U.S. Food and Drug Administration approved Remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease.” The other countries using it are : Japan, United Kingdom, South Korea, Taiwan, India, Singapore, Israel, European Union and Australia.

There are many reports of people requesting to NOT be treated with Remdesivir but rather get ivermectin, only to be told it is NOT approved as treatment for Covid 19. Dr Ardis says it is an outright lie and he points to NIH own website where covid19 treatment guidelines are outlined: Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19. Where we find the second drug mentioned is Ivermectin protocol for Adults is:  “The dose most commonly used in clinical trials is IVM 0.2–0.6 mg/kg PO given as a single dose or as a once-daily dose for up to 5 days.”

In view of these facts there are but very few explanation for this treatment strategy where effective treatment is denied and a killing apparatus is deployed. Of course one can not underestimate incompetence from top to bottom, but I shell leave you to draw you your own conclusions. 


Good things come to those who sign up

Leave a Reply